Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Advanced Hematological Malignancies

Trial Profile

Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Advanced Hematological Malignancies

Completed
Phase of Trial: Phase I

Latest Information Update: 09 May 2016

At a glance

  • Drugs TG 02 (Primary) ; Carfilzomib; Dexamethasone
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Chronic myeloid leukaemia; Multiple myeloma; Myelodysplastic syndromes
  • Focus Adverse reactions
  • Sponsors Tragara Pharmaceuticals
  • Most Recent Events

    • 05 May 2016 Status changed from recruiting to completed.
    • 12 Nov 2015 According to a Tragara Pharmaceuticals media release, clinical proof-of-concept has been achieved in this study,
    • 05 Nov 2015 Planned End Date changed from 1 May 2016 to 1 Aug 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top